We are monitoring the impact of COVID-19 on Lung Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 833
Share on
Share on

Global Lung Cancer Therapeutics Market Analysis - By Treatment Type (Chemotherapy, Radiotherapy and Other Drugs) and By Region - Industry Analysis, Size, Share, Growth, Trends, Forecast | 2019 - 2024

Pulished: August, 2019
ID: 833
Pages: 180

Global Lung Cancer Therapeutics Market Size & Growth (2019 - 2024)

As per this report, the size of the Global Lung Cancer Therapeutics Market is expected to worth USD 6.43 billion in 2019 and estimated to be growing at a CAGR of 6.7%, to reach USD 8.89 billion by 2024.

Lung cancer is the second most commonly detected and has the highest death rate of all cancers in both men and women. Cigarette smoking is the projecting cause of lung cancer.

Lung cancer is a malignant tumor regarded as an uninhibited growth of cell tissues in the lung. Lung cancer declines the lung capability to deliver oxygen to the bloodstream. Some of the key indications of lung cancer comprise of appetite loss, wheezing, weight loss, coughing, mucus, shortness of breath, and chest pain.

Increasing occurrences of lung cancer because of the mounting smoking population is one of the major factors driving the growth of the global lung cancer therapeutics market. Additionally, the introduction of superior-priced drugs and new advanced radiation therapies are the major drivers fuelling market growth. Novel and safer therapies could improve opportunities for the growth of the global lung cancer therapeutics market.

However, the devices require huge amounts for installation and maintenance to have accurate results which are remained as challenging factor for the Lung Cancer Therapeutics Market developers. A dearth of skilled persons in properly managing the systems in real-time applications is slowly impeding the growth of the market. Lack of standardization is one more attribute limiting the demand of the Global Lung Cancer Therapeutics Market.

Increasing investments in healthcare centers by government and also to promote quality treatment services is lucratively leveling up growth opportunities for the global lung cancer therapeutics market. Rise in the popularity of the treatment procedures through digital advertisements is lavishing the demand of the market. Also, growing disposable income in urban areas is merely prompting the growth rate of this market to the extent. Furthermore, the market is fuelled by on-going research on the development of new technologies in favor of the end-users. The emergence of the latest technology in radiation therapies is enhancing the growth rate of the market. The rise in the economy is well developed and developing countries globally is greatly influencing the demand of the Global Lung Cancer Therapeutics Market.

Key Happenings in this market in the recent past:

  • AstraZeneca received marketing authorization approval from the National Medical Products Administration (NMPA) in September 2019 in China for Tagrisso, which is an EGFR tyrosine kinase inhibitor. This drug is used for patients with EGFR-mutated non-small cell lung cancer. The approval has provided the marketing and commercialization of drug exclusivity to Chinese firms, which will help to expand the business further.
  • F. Hoffmann-La Roche Ltd received approval from the US FDA for Cobas EGFR Mutation Test v2 in August 2018. Cobas is a liquid biopsy diagnostic test that is in general used in combination with Irresa (gefitinib), an EGFR inhibitor for the treatment of non-small cell lung cancer (NSCLC). It is the only FDA approved diagnostic test for NSCLC. This test will provide effective and safer therapy for patients with NSCLC and expands the diagnostic business segment of F. Hoffmann-La Roche Ltd.
  • In March 2019, Adorx Therapeutics Limited announced that it had entered into long-term aims and interests of partnership with Johnson & Johnson Innovation LLC and Lung Cancer Initiative at Johnson & Johnson (LCI) for the development of new novel lung cancer therapeutics. 
  • In June 2016, the American Society of Clinical Oncology (ASCO) had announced that a new antibody-drug conjugate had shown an early promise in the treatment of small-cell lung cancer.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2018 – 2024

Base Year

2018

Forecast Period

2019 - 2024

Segments Covered

By Treatment Type and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstraZeneca Plc and Sanofi-Aventi.

 

The research report on the Global Lung Cancer Therapeutics Market has been segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2024.

Lung Cancer Therapeutics Market Analysis - By Treatment Type

  • Chemotherapy
    • Cisplatin
    • Taxol
    • Navelbine
    • Camptosar
    • Alimta
  • Radiotherapy
    • External Beam
    • Internal Beam
    • Systemic
  • Other Drugs
    • Abraxane
    • Avastin
    • Crizotinib
    • Docetaxel
    • Gefitinib

By Treatment Type, Chemotherapy treatment type is growing at a faster rate form the past decade. The increasing success rate of chemotherapy due to the adoption of advanced technology is considered to be the primary factor for this segment to grow extensively. A rise in the demand for effective treatment procedures with less adverse effects is levelling up the growth of the Global Lung Cancer Therapeutics Market. Growing preference for early detection and diagnosis of the diseases is also surging the growth rate of the market. Stringent rules and regulations by the government in approving new products in concern towards people’s safety is elevating the demand for the global lung cancer therapeutics market.

Regional Analysis:

North America and Europe lead the global lung cancer therapeutics market. Lung cancer is the most common type of cancer in the U.S and the majority of the population die of lung cancer every year. Asia-Pacific countries such as India and China are the developing regions for the global lung cancer therapeutics market owing to the high occurrence of this disease along with growing healthcare alertness.

Companies are implementing various strategies to increase their product portfolio and raise their geographical presence. New product expansion, contracts, and associations, and procurements are some of the significant approaches adopted by the manufacturers in the lung cancer therapeutics market.

List of key market participants dominating the Global Lung Cancer Therapeutics Market profiled in this report are:

  1. Boehringer Ingelheim GmbH
  2. Hoffman-La Roche
  3. Pfizer Inc.
  4. GlaxoSmithKline
  5. Eli Lilly and Company
  6. Agennix AG
  7. AstraZeneca Plc
  8. Sanofi-Aventi

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Treatment Type                                 

                                5.1.1 Chemotherapy                     

                                                5.1.1.1 Cisplatin

                                                5.1.1.2 Taxol      

                                                5.1.1.3 Navelbine            

                                                5.1.1.4 Camptosar          

                                                5.1.1.5 Alimta   

                                5.1.2 Radiotherapy                         

                                                5.1.2.1 External Beam   

                                                5.1.2.2 Internal Beam    

                                                5.1.2.3 Systemic              

                                5.1.3 Other Drugs                            

                                                5.1.3.1 Abraxane             

                                                5.1.3.2 Avastin 

                                                5.1.3.3 Crizotinib             

                                                5.1.3.4 Docetaxel            

                                                5.1.3.5 Gefitinib               

6. Geographical Analysis                                                              

                6.1 North America                                          

                                6.1.1 Introduction                           

                                6.1.2 United States                         

                                6.1.3 Canada                     

                6.2 Europe                                         

                                6.2.1 Introduction                           

                                6.2.2 U.K                             

                                6.2.3 Spain                         

                                6.2.4 Germany                 

                                6.2.5 Italy                           

                                6.2.6 France                      

                6.3 Asia-Pacific                                 

                                6.3.1 Introduction                           

                                6.3.2 China                         

                                6.3.3 India                          

                                6.3.4 Japan                        

                                6.3.5 South Korea                           

                                6.3.6 Australia                  

                6.4 Latin America                                            

                                6.4.1 Introduction                           

                                6.4.2 Brazil                         

                                6.4.3 Mexico                     

                                6.4.4 Argentina                

                                6.4.5 Rest of Latin America                         

                6.5 Middle East & Africa                               

                                6.5.1 Introduction                           

                                6.5.2 Middle-East                            

                                6.5.3 Africa                        

7. Pipeline Product Analysis                                                       

                7.1 Overview                                                    

                7.2 Pipeline Development Landscape                                                    

                7.3 Molecular Targets in the Pipeline                                                     

                7.4 Clinical Trials                                             

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target                       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                                  

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.                               

8. Strategic Analysis                                                       

                8.1 PESTLE analysis                                         

                                8.1.1 Political                     

                                8.1.2 Economic                 

                                8.1.3 Social                         

                                8.1.4 Technological                         

                                8.1.5 Legal                          

                                8.1.6 Environmental                      

                8.2 Porter’s Five analysis                                              

                                8.2.1 Bargaining Power of Suppliers                        

                                8.2.2 Bargaining Power of Consumers                    

                                8.2.3 Threat of New Entrants                     

                                8.2.4 Threat of Substitute Products and Services               

                                8.2.5 Competitive Rivalry within the Industry                      

9. Market Leaders' Analysis                                                        

                9.1 BoehringerIngelheim GmbH                               

                                9.1.1 Overview                

                                9.1.2 Product Analysis                   

                                9.1.3 Strategic Evaluation and Operations                            

                                9.1.4 Financial analysis                  

                                9.1.5 Legal issues                            

                                9.1.6 Recent Developments                       

                                9.1.7 SWOT analysis                       

                                9.1.8 Analyst View                          

                9.2 Hoffman-La Roche                                  

                9.3 Pfizer Inc.                                    

                9.4 GlaxoSmitKline                                         

                9.5 Eli Lilly and Company                                             

                9.6 AstrazenecaPlc                                         

                9.7 Sanofi-Aventis                                          

                9.8 Agennix AG                                

10. Competitive Landscape                                                         

                10.1 Market share analysis                                          

                10.2 Merger and Acquisition Analysis                                     

                10.3 Agreements, collaborations and Joint Ventures                                       

                10.4 New Product Launches                                       

11. Expert Opinions                                                        

                11.1 Market Outlook                                     

                11.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Lung Cancer Therapeutics Market By Region, From 2019-2024 (USD Billion)
  2. Global Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  3. Global Chemotherapy Market By Region, From 2019-2024 (USD Billion)
  4. Global Radiotherapy Market By Region, From 2019-2024 (USD Billion)
  5. Global Other Lung Cancer Therapeutic Drugs Market By Region, From 2019-2024 (USD Billion)
  6. Global Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  7. Global Cisplatin Market By Region, From 2019-2024 (USD Billion)
  8. Global Taxol Market By Region, From 2019-2024 (USD Billion)
  9. Global Navelbine Market By Region, From 2019-2024 (USD Billion)
  10. Global Camptosar Market By Region, From 2019-2024 (USD Billion)
  11. Global Alimta Market By Region, From 2019-2024 (USD Billion)
  12. Global Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  13. Global External Beam Market By Region, From 2019-2024 (USD Billion)
  14. Global Internal Beam Market By Region, From 2019-2024 (USD Billion)
  15. Global Systemic Market By Region, From 2019-2024 (USD Billion)
  16. Global Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  17. Global Abraxane Market By Region, From 2019-2024 (USD Billion)
  18. Global Avastin Market By Region, From 2019-2024 (USD Billion)
  19. Global Crizotinib Market By Region, From 2019-2024 (USD Billion)
  20. Global Docetaxel Market By Region, From 2019-2024 (USD Billion)
  21. Global Gefitinib Market By Region, From 2019-2024 (USD Billion)
  22. North America Lung Cancer Therapeutics Market By Region, From 2019-2024 (USD Billion)
  23. North America Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  24. North America Chemotherapy Market By Region, From 2019-2024 (USD Billion)
  25. North America Radiotherapy Market By Region, From 2019-2024 (USD Billion)
  26. North America Other Lung Cancer Therapeutic Drugs Market By Region, From 2019-2024 (USD Billion)
  27. United States Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  28. Canada Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  29. North America Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  30. North America Cisplatin Market By Region, From 2019-2024 (USD Billion)
  31. North America Taxol Market By Region, From 2019-2024 (USD Billion)
  32. North America Navelbine Market By Region, From 2019-2024 (USD Billion)
  33. North America Camptosar Market By Region, From 2019-2024 (USD Billion)
  34. North America Alimta Market By Region, From 2019-2024 (USD Billion)
  35. United States Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  36. Canada Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  37. North America Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  38. North America External Beam Market By Region, From 2019-2024 (USD Billion)
  39. North America Internal Beam Market By Region, From 2019-2024 (USD Billion)
  40. North America Systemic Market By Region, From 2019-2024 (USD Billion)
  41. United States Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  42. Canada Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  43. North America Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  44. North America Abraxane Market By Region, From 2019-2024 (USD Billion)
  45. North America Avastin Market By Region, From 2019-2024 (USD Billion)
  46. North America Crizotinib Market By Region, From 2019-2024 (USD Billion)
  47. North America Docetaxel Market By Region, From 2019-2024 (USD Billion)
  48. North America Gefitinib Market By Region, From 2019-2024 (USD Billion)
  49. United States Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  50. Canada Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  51. Europe Lung Cancer Therapeutics Market By Region, From 2019-2024 (USD Billion)
  52. Europe Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  53. Europe Chemotherapy Market By Region, From 2019-2024 (USD Billion)
  54. Europe Radiotherapy Market By Region, From 2019-2024 (USD Billion)
  55. Europe Other Lung Cancer Therapeutic Drugs Market By Region, From 2019-2024 (USD Billion)
  56. U.K Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  57. Spain Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  58. Germany Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  59. Italy Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  60. France Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  61. Europe Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  62. Europe Cisplatin Market By Region, From 2019-2024 (USD Billion)
  63. Europe Taxol Market By Region, From 2019-2024 (USD Billion)
  64. Europe Navelbine Market By Region, From 2019-2024 (USD Billion)
  65. Europe Camptosar Market By Region, From 2019-2024 (USD Billion)
  66. Europe Alimta Market By Region, From 2019-2024 (USD Billion)
  67. U.K Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  68. Spain Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  69. Germany Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  70. Italy Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  71. France Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  72. Europe Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  73. Europe External Beam Market By Region, From 2019-2024 (USD Billion)
  74. Europe Internal Beam Market By Region, From 2019-2024 (USD Billion)
  75. Europe Systemic Market By Region, From 2019-2024 (USD Billion)
  76. U.K Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  77. Spain Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  78. Germany Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  79. Italy Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  80. France Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  81. Europe Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  82. Europe Abraxane Market By Region, From 2019-2024 (USD Billion)
  83. Europe Avastin Market By Region, From 2019-2024 (USD Billion)
  84. Europe Crizotinib Market By Region, From 2019-2024 (USD Billion)
  85. Europe Docetaxel Market By Region, From 2019-2024 (USD Billion)
  86. Europe Gefitinib Market By Region, From 2019-2024 (USD Billion)
  87. U.K Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  88. Spain Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  89. Germany Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  90. Italy Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  91. France Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  92. Asia-Pacific Lung Cancer Therapeutics Market By Region, From 2019-2024 (USD Billion)
  93. Asia-Pacific Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  94. Asia-Pacific Chemotherapy Market By Region, From 2019-2024 (USD Billion)
  95. Asia-Pacific Radiotherapy Market By Region, From 2019-2024 (USD Billion)
  96. Asia-Pacific Other Lung Cancer Therapeutic Drugs Market By Region, From 2019-2024 (USD Billion)
  97. China Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  98. India Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  99. Japan Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  100. South Korea Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  101. Australia Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  102. Asia-Pacific Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  103. Asia-Pacific Cisplatin Market By Region, From 2019-2024 (USD Billion)
  104. Asia-Pacific Taxol Market By Region, From 2019-2024 (USD Billion)
  105. Asia-Pacific Navelbine Market By Region, From 2019-2024 (USD Billion)
  106. Asia-Pacific Camptosar Market By Region, From 2019-2024 (USD Billion)
  107. Asia-Pacific Alimta Market By Region, From 2019-2024 (USD Billion)
  108. China Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  109. India Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  110. Japan Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  111. South Korea Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  112. Australia Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  113. Asia-Pacific Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  114. Asia-Pacific External Beam Market By Region, From 2019-2024 (USD Billion)
  115. Asia-Pacific Internal Beam Market By Region, From 2019-2024 (USD Billion)
  116. Asia-Pacific Systemic Market By Region, From 2019-2024 (USD Billion)
  117. China Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  118. India Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  119. Japan Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  120. South Korea Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  121. Australia Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  122. Asia-Pacific Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  123. Asia-Pacific Abraxane Market By Region, From 2019-2024 (USD Billion)
  124. Asia-Pacific Avastin Market By Region, From 2019-2024 (USD Billion)
  125. Asia-Pacific Crizotinib Market By Region, From 2019-2024 (USD Billion)
  126. Asia-Pacific Docetaxel Market By Region, From 2019-2024 (USD Billion)
  127. Asia-Pacific Gefitinib Market By Region, From 2019-2024 (USD Billion)
  128. China Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  129. India Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  130. Japan Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  131. South Korea Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  132. Australia Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  133. Latin America Lung Cancer Therapeutics Market By Region, From 2019-2024 (USD Billion)
  134. Latin America Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  135. Latin America Chemotherapy Market By Region, From 2019-2024 (USD Billion)
  136. Latin America Radiotherapy Market By Region, From 2019-2024 (USD Billion)
  137. Latin America Other Lung Cancer Therapeutic Drugs Market By Region, From 2019-2024 (USD Billion)
  138. Brazil Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  139. Argentina Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  140. Mexico Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  141. Latin America Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  142. Latin America Cisplatin Market By Region, From 2019-2024 (USD Billion)
  143. Latin America Taxol Market By Region, From 2019-2024 (USD Billion)
  144. Latin America Navelbine Market By Region, From 2019-2024 (USD Billion)
  145. Latin America Camptosar Market By Region, From 2019-2024 (USD Billion)
  146. Latin America Alimta Market By Region, From 2019-2024 (USD Billion)
  147. Brazil Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  148. Argentina Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  149. Mexico Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  150. Latin America Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  151. Latin America External Beam Market By Region, From 2019-2024 (USD Billion)
  152. Latin America Internal Beam Market By Region, From 2019-2024 (USD Billion)
  153. Latin America Systemic Market By Region, From 2019-2024 (USD Billion)
  154. Brazil Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  155. Argentina Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  156. Mexico Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  157. Latin America Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  158. Latin America Abraxane Market By Region, From 2019-2024 (USD Billion)
  159. Latin America Avastin Market By Region, From 2019-2024 (USD Billion)
  160. Latin America Crizotinib Market By Region, From 2019-2024 (USD Billion)
  161. Latin America Docetaxel Market By Region, From 2019-2024 (USD Billion)
  162. Latin America Gefitinib Market By Region, From 2019-2024 (USD Billion)
  163. Brazil Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  164. Argentina Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  165. Mexico Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  166. Middle East & Africa Lung Cancer Therapeutics Market By Region, From 2019-2024 (USD Billion)
  167. Middle East & Africa Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  168. Middle East & Africa Chemotherapy Market By Region, From 2019-2024 (USD Billion)
  169. Middle East & Africa Radiotherapy Market By Region, From 2019-2024 (USD Billion)
  170. Middle East & Africa Other Lung Cancer Therapeutic Drugs Market By Region, From 2019-2024 (USD Billion)
  171. Middle East Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  172. Africa Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  173. Middle East & Africa Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  174. Middle East & Africa Cisplatin Market By Region, From 2019-2024 (USD Billion)
  175. Middle East & Africa Taxol Market By Region, From 2019-2024 (USD Billion)
  176. Middle East & Africa Navelbine Market By Region, From 2019-2024 (USD Billion)
  177. Middle East & Africa Camptosar Market By Region, From 2019-2024 (USD Billion)
  178. Middle East & Africa Alimta Market By Region, From 2019-2024 (USD Billion)
  179. Middle East Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  180. Africa Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  181. Middle East & Africa Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  182. Middle East & Africa External Beam Market By Region, From 2019-2024 (USD Billion)
  183. Middle East & Africa Internal Beam Market By Region, From 2019-2024 (USD Billion)
  184. Middle East & Africa Systemic Market By Region, From 2019-2024 (USD Billion)
  185. Middle East Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  186. Africa Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  187. Middle East & Africa Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  188. Middle East & Africa Abraxane Market By Region, From 2019-2024 (USD Billion)
  189. Middle East & Africa Avastin Market By Region, From 2019-2024 (USD Billion)
  190. Middle East & Africa Crizotinib Market By Region, From 2019-2024 (USD Billion)
  191. Middle East & Africa Docetaxel Market By Region, From 2019-2024 (USD Billion)
  192. Middle East & Africa Gefitinib Market By Region, From 2019-2024 (USD Billion)
  193. Middle East Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  194. Africa Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample